Monthly Archives: May 2017

http://www.lslog.com/safety-profile-will-help-bring-ozanimod-to-multiple-sclerosis-market-says-celgene/Safety profile will help bring ozanimod to multiple sclerosis market, says Celgene

Safety profile will help bring ozanimod to multiple sclerosis market, says Celgene

Safety profile will help bring ozanimod to multiple sclerosis market, says Celgene Missing a secondary endpoint in the RADIANCE trial won’t hinder the launch or commercial success of ozanimod, CFO […]

http://www.lslog.com/gottlieb-ends-fda-hiring-freeze-lays-out-rd-priorities/Gottlieb ends FDA hiring freeze, lays out R&D priorities

Gottlieb ends FDA hiring freeze, lays out R&D priorities

Gottlieb ends FDA hiring freeze, lays out R&D priorities Scott Gottlieb, M.D., has ended the hiring freeze President Donald Trump imposed on the FDA. The action means Gottlieb can fill […]

http://www.lslog.com/chutes-ladders-alexions-c-suite-overhaul-involves-cfo-rd-head/Chutes & Ladders—Alexion’s C-suite overhaul involves CFO, R&D head

Chutes & Ladders—Alexion’s C-suite overhaul involves CFO, R&D head

Chutes & Ladders—Alexion’s C-suite overhaul involves CFO, R&D head Alexion experienced a major C-suite overhaul that included its CFO, CCO, R&D head and HR chief; Van Oene’s title as Illumina’s […]

http://www.lslog.com/trio-of-patients-sue-pfizer-bms-claiming-they-soft-pedaled-eliquis-bleeding-risks/Trio of patients sue Pfizer, BMS, claiming they soft-pedaled Eliquis bleeding risks

Trio of patients sue Pfizer, BMS, claiming they soft-pedaled Eliquis bleeding risks

Trio of patients sue Pfizer, BMS, claiming they soft-pedaled Eliquis bleeding risks Just two weeks after convincing a judge in New York to toss a liability case over Eliquis bleeding […]

http://www.lslog.com/fda-panel-backs-pfizer-biosim-to-blockbuster-anemia-meds-from-amgen-johnson-johnson/FDA panel backs Pfizer biosim to blockbuster anemia meds from Amgen, Johnson & Johnson

FDA panel backs Pfizer biosim to blockbuster anemia meds from Amgen, Johnson & Johnson

FDA panel backs Pfizer biosim to blockbuster anemia meds from Amgen, Johnson & Johnson Pfizer’s biosimilar to blockbuster anemia meds—Amgen’s Epogen and Johnson & Johnson’s Procrit—won the support of an […]

http://www.lslog.com/harpoon-therapeutics-hits-45m-in-series-b-for-i-o-work/Harpoon Therapeutics hits $45M in series B for I-O work

Harpoon Therapeutics hits $45M in series B for I-O work

Harpoon Therapeutics hits M in series B for I-O work Harpoon Therapeutics has raised $45 million in its second funding round as it looks to get its I-O candidates into […]

http://www.lslog.com/first-ocrevus-patient-comes-down-with-pml-but-is-the-roche-med-really-to-blame/First Ocrevus patient comes down with PML—but is the Roche med really to blame?

First Ocrevus patient comes down with PML—but is the Roche med really to blame?

First Ocrevus patient comes down with PML—but is the Roche med really to blame? Roche’s new drug Ocrevus has landed in the same sentence with the three letters all multiple […]

http://www.lslog.com/novartis-adds-to-biologics-manufacturing-in-midst-of-global-job-cutting/Novartis adds to biologics manufacturing in midst of global job cutting

Novartis adds to biologics manufacturing in midst of global job cutting

Novartis adds to biologics manufacturing in midst of global job cutting Novartis’ is adding jobs to its biologics manufacturing operations even as the Swiss company makes cuts across other parts […]

http://www.lslog.com/funding-uncertainty-could-dent-u-k-s-role-as-euro-biotech-hub-says-bia/Funding uncertainty could dent U.K.'s role as Euro biotech hub, says BIA

Funding uncertainty could dent U.K.'s role as Euro biotech hub, says BIA

Funding uncertainty could dent U.K.’s role as Euro biotech hub, says BIA The U.K. has been closing the gap on the leading life sciences sectors in Boston and the San […]

http://www.lslog.com/takeda-and-nea-back-39m-series-a-for-gi-biotech-orphomed/Takeda and NEA back $39M series A for GI biotech OrphoMed

Takeda and NEA back $39M series A for GI biotech OrphoMed

Takeda and NEA back M series A for GI biotech OrphoMed OrphoMed gained a $39 million early funding boost from a Japanese big pharma and a host of VCs as […]